Rebecca Wicklein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca Wicklein has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Knier
Department of Neurology, TUM University Hospital, School of Medicine and Health, Technical University of Munich, Germany
7 shared publications - Bernhard Hemmer
Department of Neurology, School of Medicine and Health, Technical University of Munich, Germany
6 shared publications - Lilian Aly
Department of Neurology, Klinikum rechts der Isar, TUM School of Medicine and Health, Technical University of Munich, Munich, Germany
4 shared publications - Achim Berthele
Department of Neurology, School of Medicine and Health, Technical University of Munich, Germany
3 shared publications - Christian Mardin
Universitätsklinikum Erlangen
3 shared publications - Elisabeth Wolf
Department of Neurology, TUM University Hospital, TUM School of Medicine and Health, Technical University of Munich, Germany; and
3 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6) , e200668
MOG Antibody Status Is Associated With Distinct Clinical Profiles and Treatment Responses in Chronic Relapsing Inflammatory Optic Neuropathy
Chronic relapsing inflammatory optic neuropathy (CRION) is a steroid-dependent form of optic neuritis with incompletely understood pathophysiology. The identification of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in a substantial patient subset has challenged the diagnostic and therapeutic management. The aim of this study was to investigate clinical profiles and treatment outcomes of patients with CRION, comparing MOG-IgG-positive (MOG+) and seronegative (MOG-) subgroups. Patients from 6 European tertiary centers fulfilling diagnostic criteria for CRION were included. All underwent cell-based autoantibody testing. Clinical outcomes (visual acuity and annualized relapse rate), laboratory and imaging findings (MRI, OCT), and treatment responses were retrospectively analyzed. Sixty patients were included (median age 33 years; 70% female); 27 (45%) were MOG+. MOG+ CRION was associated with later onset, higher annualized relapse rate (ARR) before treatment (median [IQR] 2 [1-3] vs 1 [1-2], p = 0.023), and a trend toward shorter interrelapse intervals. Additional distinguishing features included higher frequencies of antinuclear antibody positivity, elevated CSF interleukin-6, and extensive enhancement of the optic nerve on MRI. Relapse burden correlated with visual acuity decline and retinal thinning. In MOG+ patients, monoclonal antibody therapy reduced the ARR (n = 21; 2 [1-3] vs 0 [0-2], p = 0.024), primarily driven by tocilizumab (n = 11; 2 [1-3] vs 0 [0-1], p = 0.023). In MOG- patients, rituximab and azathioprine showed a trend toward ARR reduction. CRION represents a heterogeneous syndrome encompassing distinct subgroups. Although MOG+ patients demonstrate higher disease activity, tocilizumab might represent a therapeutic option, though further validation is needed. Serologic testing is critical for treatment stratification and preventing relapses.
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6) , e200668
MOG Antibody Status Is Associated With Distinct Clinical Profiles and Treatment Responses in Chronic Relapsing Inflammatory Optic Neuropathy
Chronic relapsing inflammatory optic neuropathy (CRION) is a steroid-dependent form of optic neuritis with incompletely understood pathophysiology. The identification of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in a substantial patient subset has challenged the diagnostic and therapeutic management. The aim of this study was to investigate clinical profiles and treatment outcomes of patients with CRION, comparing MOG-IgG-positive (MOG+) and seronegative (MOG-) subgroups. Patients from 6 European tertiary centers fulfilling diagnostic criteria for CRION were included. All underwent cell-based autoantibody testing. Clinical outcomes (visual acuity and annualized relapse rate), laboratory and imaging findings (MRI, OCT), and treatment responses were retrospectively analyzed. Sixty patients were included (median age 33 years; 70% female); 27 (45%) were MOG+. MOG+ CRION was associated with later onset, higher annualized relapse rate (ARR) before treatment (median [IQR] 2 [1-3] vs 1 [1-2], p = 0.023), and a trend toward shorter interrelapse intervals. Additional distinguishing features included higher frequencies of antinuclear antibody positivity, elevated CSF interleukin-6, and extensive enhancement of the optic nerve on MRI. Relapse burden correlated with visual acuity decline and retinal thinning. In MOG+ patients, monoclonal antibody therapy reduced the ARR (n = 21; 2 [1-3] vs 0 [0-2], p = 0.024), primarily driven by tocilizumab (n = 11; 2 [1-3] vs 0 [0-1], p = 0.023). In MOG- patients, rituximab and azathioprine showed a trend toward ARR reduction. CRION represents a heterogeneous syndrome encompassing distinct subgroups. Although MOG+ patients demonstrate higher disease activity, tocilizumab might represent a therapeutic option, though further validation is needed. Serologic testing is critical for treatment stratification and preventing relapses.
- Open Access
- 23 October 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
Availability of resources to apply the 2024 McDonald criteria: A global perspective
Background: The 3rd ECTRIMS Winter School highlighted regional and global disparities in resources needed to implement the 2024 McDonald diagnostic criteria for multiple sclerosis. Objectives: To assess the availability of paraclinical tools and regional differences in access reported by neurologists in an online survey. Results: The survey was completed by 328 neurologists from 44 countries. Core diagnostic tools, including magnetic resonance imaging and oligoclonal band testing, were widely available. Access to advanced imaging, optic nerve assessment, and laboratory biomarkers varied across regions. Conclusions: Variability in access to key paraclinical tests may impact on the implementation of the 2024 McDonald criteria globally.
- 23 October 2026
- Published by SAGE Publications in Multiple Sclerosis Journal
Open AccessAvailability of resources to apply the 2024 McDonald criteria: A global perspective
Background: The 3rd ECTRIMS Winter School highlighted regional and global disparities in resources needed to implement the 2024 McDonald diagnostic criteria for multiple sclerosis. Objectives: To assess the availability of paraclinical tools and regional differences in access reported by neurologists in an online survey. Results: The survey was completed by 328 neurologists from 44 countries. Core diagnostic tools, including magnetic resonance imaging and oligoclonal band testing, were widely available. Access to advanced imaging, optic nerve assessment, and laboratory biomarkers varied across regions. Conclusions: Variability in access to key paraclinical tests may impact on the implementation of the 2024 McDonald criteria globally.
- Open Access
- 28 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71612
Retinal Layer Thickness for Risk Stratification of Progression Independent of Relapse Activity in Relapsing‐Remitting Multiple Sclerosis
Background: Identifying people with relapsing‐remitting multiple sclerosis (pwRRMS) at risk of progression independent of relapse activity (PIRA) remains an unmet clinical need. Optical coherence tomography (OCT)‐derived measures of retinal neuroaxonal damage may provide prognostic value. This study aimed to evaluate whether peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell‐inner plexiform layer (GCIP) thickness predict PIRA within a heterogenous group of pwRRMS. Methods: We retrospectively screened pwRRMS with ≥ 2 years relapse‐free follow‐up from prospective observational cohort studies in Berlin ( n = 74) and Munich ( n = 146). PIRA was defined as disability worsening, determined by method‐specific thresholds across multimodal assessments, sustained until end of follow‐up. Analyses were restricted to non‐optic neuritis eyes. Cox hazard models were used to assess the adjusted hazard (aHR) of PIRA with age‐adjusted pRNFL or GCIP Z ‐scores. Results: Out of 220 pwRRMS (age: 38.1 ± 9.9 years), 65 (29.5%) developed PIRA over a follow‐up of 2.9 [IQR: 1.6–4.1] years. No associations between OCT measures and PIRA were found within the overall study population or Munich cohort. In the Berlin cohort, thinner pRNFL predicted PIRA (aHR [95% CI] = 1.41 [1.03–1.92], p = 0.032), while GCIP did not (aHR [95% CI] = 1.38 [0.90–2.10], p = 0.140). Conclusions: OCT measurements do not predict the hazard of PIRA within a heterogeneous group of pwRRMS. However, they have potential prognostic value in early disease stages. Clinical characteristics might influence the association and require further investigation.
- 28 July 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (8) , e71612
Open AccessRetinal Layer Thickness for Risk Stratification of Progression Independent of Relapse Activity in Relapsing‐Remitting Multiple Sclerosis
Background: Identifying people with relapsing‐remitting multiple sclerosis (pwRRMS) at risk of progression independent of relapse activity (PIRA) remains an unmet clinical need. Optical coherence tomography (OCT)‐derived measures of retinal neuroaxonal damage may provide prognostic value. This study aimed to evaluate whether peripapillary retinal nerve fiber layer (pRNFL) and ganglion cell‐inner plexiform layer (GCIP) thickness predict PIRA within a heterogenous group of pwRRMS. Methods: We retrospectively screened pwRRMS with ≥ 2 years relapse‐free follow‐up from prospective observational cohort studies in Berlin ( n = 74) and Munich ( n = 146). PIRA was defined as disability worsening, determined by method‐specific thresholds across multimodal assessments, sustained until end of follow‐up. Analyses were restricted to non‐optic neuritis eyes. Cox hazard models were used to assess the adjusted hazard (aHR) of PIRA with age‐adjusted pRNFL or GCIP Z ‐scores. Results: Out of 220 pwRRMS (age: 38.1 ± 9.9 years), 65 (29.5%) developed PIRA over a follow‐up of 2.9 [IQR: 1.6–4.1] years. No associations between OCT measures and PIRA were found within the overall study population or Munich cohort. In the Berlin cohort, thinner pRNFL predicted PIRA (aHR [95% CI] = 1.41 [1.03–1.92], p = 0.032), while GCIP did not (aHR [95% CI] = 1.38 [0.90–2.10], p = 0.140). Conclusions: OCT measurements do not predict the hazard of PIRA within a heterogeneous group of pwRRMS. However, they have potential prognostic value in early disease stages. Clinical characteristics might influence the association and require further investigation.
- Open Access
- 10 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1315.e1-1315.e11
Polyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis
- 10 June 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1315.e1-1315.e11
Open AccessPolyomavirus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Multicenter Retrospective Analysis
- Open Access
MOG Antibody Status Shapes Divergent Clinical Profiles And Therapeutic Responses In Chronic Relapsing Inflammatory Optic Neuropathy
Background: Chronic relapsing inflammatory optic neuropathy (CRION) is a steroid-dependent form of optic neuritis with incompletely understood pathophysiology. The identification of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in a substantial patient subset has challenged the diagnostic and therapeutic management. The aim of this study was to investigate clinical profiles and treatment outcomes of patients with CRION, comparing MOG-IgG-positive (MOG+) and seronegative (MOG-) subgroups. Methods: Patients from six European tertiary centers fulfilling diagnostic criteria for CRION were included. All underwent cell-based autoantibody testing. Clinical outcomes (visual acuity, annualized relapse rate), laboratory and imaging findings (MRI, OCT), and treatment responses were retrospectively analyzed. Results: Sixty patients were included (median age 33 years; 70% female); 27 (45%) were MOG+. MOG+ CRION was associated with later onset, higher ARR before treatment (median [IQR] 2 [1-3] vs. 1 [1-2], p = 0.023), and a trend toward shorter inter-relapse intervals. Additional distinguishing features included higher frequencies of antinuclear antibody positivity, elevated CSF interleukin-6, and extensive optic neuritis on MRI. Relapse burden correlated with visual acuity decline and retinal thinning. In MOG+ patients, monoclonal antibody therapy reduced the ARR (n = 21; 2 [1-3] vs. 0 [0-2], p = 0.024), primarily driven by tocilizumab (n = 11; 2 [1-3] vs. 0 [0-1], p = 0.023). In MOG-patients, rituximab and azathioprine showed a trend toward ARR reduction. Conclusion: CRION represents a heterogeneous syndrome encompassing distinct subgroups. MOG+ patients demonstrate higher disease activity but respond favorably to tocilizumab. Serological testing is critical for treatment stratification and preventing relapses.
Open AccessMOG Antibody Status Shapes Divergent Clinical Profiles And Therapeutic Responses In Chronic Relapsing Inflammatory Optic Neuropathy
Background: Chronic relapsing inflammatory optic neuropathy (CRION) is a steroid-dependent form of optic neuritis with incompletely understood pathophysiology. The identification of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in a substantial patient subset has challenged the diagnostic and therapeutic management. The aim of this study was to investigate clinical profiles and treatment outcomes of patients with CRION, comparing MOG-IgG-positive (MOG+) and seronegative (MOG-) subgroups. Methods: Patients from six European tertiary centers fulfilling diagnostic criteria for CRION were included. All underwent cell-based autoantibody testing. Clinical outcomes (visual acuity, annualized relapse rate), laboratory and imaging findings (MRI, OCT), and treatment responses were retrospectively analyzed. Results: Sixty patients were included (median age 33 years; 70% female); 27 (45%) were MOG+. MOG+ CRION was associated with later onset, higher ARR before treatment (median [IQR] 2 [1-3] vs. 1 [1-2], p = 0.023), and a trend toward shorter inter-relapse intervals. Additional distinguishing features included higher frequencies of antinuclear antibody positivity, elevated CSF interleukin-6, and extensive optic neuritis on MRI. Relapse burden correlated with visual acuity decline and retinal thinning. In MOG+ patients, monoclonal antibody therapy reduced the ARR (n = 21; 2 [1-3] vs. 0 [0-2], p = 0.024), primarily driven by tocilizumab (n = 11; 2 [1-3] vs. 0 [0-1], p = 0.023). In MOG-patients, rituximab and azathioprine showed a trend toward ARR reduction. Conclusion: CRION represents a heterogeneous syndrome encompassing distinct subgroups. MOG+ patients demonstrate higher disease activity but respond favorably to tocilizumab. Serological testing is critical for treatment stratification and preventing relapses.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (1) , e200509
Quality Control for Retinal Optical Coherence Tomography Angiography in Multiple Sclerosis
Optical coherence tomography angiography (OCTA) is widely used for evaluating retinal vessels. The aim of this study was to assess the influence of OCTA quality, as measured by the previously introduced OSCAR-MP criteria, on OCTA outcome parameters and the reliability of test-retest results. In this prospective longitudinal cohort study, we performed retinal OCTA at baseline and within 24 hours in 54 participants, including 42 healthy individuals and 12 patients with demyelinating CNS disease. We performed reliability testing on OCTA outcome parameters based on QC status according to the OSCAR-MP criteria. Retinal vessel density measurements remained consistent between baseline and follow-up scans when both passed quality control. By contrast, vessel densities were significantly higher in high-quality images than in paired lower quality ones. Reliability measures, such as intraclass correlation coefficient (ICC) and Pearson r, were higher in pairs where both images met quality standards, with a lower coefficient of repeatability and minimal detectable change observed. Poor OCTA image quality negatively affects retinal vessel density measurements. Implementing OSCAR-MP quality criteria demonstrated strong test-retest reliability in high-quality OCTA images, indicating its potential role as reliable quality criteria for OCTA in future clinical trials and research settings.
- 1 January 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (1) , e200509
Open AccessQuality Control for Retinal Optical Coherence Tomography Angiography in Multiple Sclerosis
Optical coherence tomography angiography (OCTA) is widely used for evaluating retinal vessels. The aim of this study was to assess the influence of OCTA quality, as measured by the previously introduced OSCAR-MP criteria, on OCTA outcome parameters and the reliability of test-retest results. In this prospective longitudinal cohort study, we performed retinal OCTA at baseline and within 24 hours in 54 participants, including 42 healthy individuals and 12 patients with demyelinating CNS disease. We performed reliability testing on OCTA outcome parameters based on QC status according to the OSCAR-MP criteria. Retinal vessel density measurements remained consistent between baseline and follow-up scans when both passed quality control. By contrast, vessel densities were significantly higher in high-quality images than in paired lower quality ones. Reliability measures, such as intraclass correlation coefficient (ICC) and Pearson r, were higher in pairs where both images met quality standards, with a lower coefficient of repeatability and minimal detectable change observed. Poor OCTA image quality negatively affects retinal vessel density measurements. Implementing OSCAR-MP quality criteria demonstrated strong test-retest reliability in high-quality OCTA images, indicating its potential role as reliable quality criteria for OCTA in future clinical trials and research settings.
- Open Access
- 14 May 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4610-4619
Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjögren’s syndrome
Background: While retinal vessel changes are evident in the eyes of patients with relapsing–remitting multiple sclerosis (RRMS), changes in the vasculature of possible MS mimics such as primary Sjögren’s syndrome (pSS) remain to be determined. We investigated the potential of retinal optical coherence tomography (OCT) angiography (OCTA) as diagnostic tool to differentiate between patients with RRMS and pSS. Methods: This cross-sectional study included patients with RRMS (n = 36), pSS (n = 36) and healthy controls (n = 30). Participants underwent clinical examination, assessment of visual acuity, retinal OCT, OCTA, and serum markers of glial and neuronal damage. We investigated the associations between OCTA parameters, visual functions, and serum markers. Eyes with a history of optic neuritis (ON) were excluded from analysis. Results: We observed a significant thinning of the combined ganglion cell and inner plexiform layer in the eyes of patients with RRMS but not with pSS, when compared to healthy controls. Retinal vessel densities of the superficial vascular complex (SVC) were reduced in both patients with RRMS and pSS. However, retinal vessel rarefication of the deep vascular complex (DVC) was only evident in patients with pSS but not RRMS. Using multivariate regression analysis, we found that DVC vessel loss in pSS patients was associated with worse visual acuity. Conclusions: Compared to patients with RRMS, rarefication of deep retinal vessels is a unique characteristic of pSS and associated with worse visual function. Assuming a disease-specific retinal vessel pathology, these data are indicative of a differential affliction of the gliovascular complex in the retina of RRMS and pSS patients.
- 14 May 2024
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4610-4619
Open AccessOptical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjögren’s syndrome
Background: While retinal vessel changes are evident in the eyes of patients with relapsing–remitting multiple sclerosis (RRMS), changes in the vasculature of possible MS mimics such as primary Sjögren’s syndrome (pSS) remain to be determined. We investigated the potential of retinal optical coherence tomography (OCT) angiography (OCTA) as diagnostic tool to differentiate between patients with RRMS and pSS. Methods: This cross-sectional study included patients with RRMS (n = 36), pSS (n = 36) and healthy controls (n = 30). Participants underwent clinical examination, assessment of visual acuity, retinal OCT, OCTA, and serum markers of glial and neuronal damage. We investigated the associations between OCTA parameters, visual functions, and serum markers. Eyes with a history of optic neuritis (ON) were excluded from analysis. Results: We observed a significant thinning of the combined ganglion cell and inner plexiform layer in the eyes of patients with RRMS but not with pSS, when compared to healthy controls. Retinal vessel densities of the superficial vascular complex (SVC) were reduced in both patients with RRMS and pSS. However, retinal vessel rarefication of the deep vascular complex (DVC) was only evident in patients with pSS but not RRMS. Using multivariate regression analysis, we found that DVC vessel loss in pSS patients was associated with worse visual acuity. Conclusions: Compared to patients with RRMS, rarefication of deep retinal vessels is a unique characteristic of pSS and associated with worse visual function. Assuming a disease-specific retinal vessel pathology, these data are indicative of a differential affliction of the gliovascular complex in the retina of RRMS and pSS patients.
- Open Access
- 28 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1284986
Association of retinal vessel pathology and brain atrophy in relapsing-remitting multiple sclerosis
Background: Optical coherence tomography angiography (OCTA) allows non-invasive assessment of retinal vessel structures. Thinning and loss of retinal vessels is evident in eyes of patients with multiple sclerosis (MS) and might be associated with a proinflammatory disease phenotype and worse prognosis. We investigated whether changes of the retinal vasculature are linked to brain atrophy and disability in MS.Material and methods: This study includes one longitudinal observational cohort (n=79) of patients with relapsing-remitting MS. Patients underwent annual assessment of the expanded disability status scale (EDSS), timed 25-foot walk, symbol digit modalities test (SDMT), retinal optical coherence tomography (OCT), OCTA, and brain MRI during a follow-up duration of at least 20 months. We investigated intra-individual associations between changes in the retinal architecture, vasculature, brain atrophy and disability. Eyes with a history of optic neuritis (ON) were excluded.Results: We included 79 patients with a median disease duration of 12 (interquartile range 2 - 49) months and a median EDSS of 1.0 (0 - 2.0). Longitudinal retinal axonal and ganglion cell loss were linked to grey matter atrophy, cortical atrophy, and volume loss of the putamen. We observed an association between vessel loss of the superficial vascular complex (SVC) and both grey and white matter atrophy. Both observations were independent of retinal ganglion cell loss. Moreover, patients with worsening of the EDSS and SDMT revealed a pronounced longitudinal rarefication of the SVC and the deep vascular complex.Discussion: ON-independent narrowing of the retinal vasculature might be linked to brain atrophy and disability in MS. Our findings suggest that retinal OCTA might be a new tool for monitoring neurodegeneration during MS.
- 28 November 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1284986
Open AccessAssociation of retinal vessel pathology and brain atrophy in relapsing-remitting multiple sclerosis
Background: Optical coherence tomography angiography (OCTA) allows non-invasive assessment of retinal vessel structures. Thinning and loss of retinal vessels is evident in eyes of patients with multiple sclerosis (MS) and might be associated with a proinflammatory disease phenotype and worse prognosis. We investigated whether changes of the retinal vasculature are linked to brain atrophy and disability in MS.Material and methods: This study includes one longitudinal observational cohort (n=79) of patients with relapsing-remitting MS. Patients underwent annual assessment of the expanded disability status scale (EDSS), timed 25-foot walk, symbol digit modalities test (SDMT), retinal optical coherence tomography (OCT), OCTA, and brain MRI during a follow-up duration of at least 20 months. We investigated intra-individual associations between changes in the retinal architecture, vasculature, brain atrophy and disability. Eyes with a history of optic neuritis (ON) were excluded.Results: We included 79 patients with a median disease duration of 12 (interquartile range 2 - 49) months and a median EDSS of 1.0 (0 - 2.0). Longitudinal retinal axonal and ganglion cell loss were linked to grey matter atrophy, cortical atrophy, and volume loss of the putamen. We observed an association between vessel loss of the superficial vascular complex (SVC) and both grey and white matter atrophy. Both observations were independent of retinal ganglion cell loss. Moreover, patients with worsening of the EDSS and SDMT revealed a pronounced longitudinal rarefication of the SVC and the deep vascular complex.Discussion: ON-independent narrowing of the retinal vasculature might be linked to brain atrophy and disability in MS. Our findings suggest that retinal OCTA might be a new tool for monitoring neurodegeneration during MS.
- Open Access
- 1 November 2023
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 10 (6)
The OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography
Background and Objectives Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. Methods To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. Results We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. Discussion We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies.
- 1 November 2023
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 10 (6)
Open AccessThe OSCAR-MP Consensus Criteria for Quality Assessment of Retinal Optical Coherence Tomography Angiography
Background and Objectives Optical coherence tomography angiography (OCTA) is a noninvasive high-resolution imaging technique for assessing the retinal vasculature and is increasingly used in various ophthalmologic, neuro-ophthalmologic, and neurologic diseases. To date, there are no validated consensus criteria for quality control (QC) of OCTA. Our study aimed to develop criteria for OCTA quality assessment. Methods To establish criteria through (1) extensive literature review on OCTA artifacts and image quality to generate standardized and easy-to-apply OCTA QC criteria, (2) application of OCTA QC criteria to evaluate interrater agreement, (3) identification of reasons for interrater disagreement, revision of OCTA QC criteria, development of OCTA QC scoring guide and training set, and (4) validation of QC criteria in an international, interdisciplinary multicenter study. Results We identified 7 major aspects that affect OCTA quality: (O) obvious problems, (S) signal strength, (C) centration, (A) algorithm failure, (R) retinal pathology, (M) motion artifacts, and (P) projection artifacts. Seven independent raters applied the OSCAR-MP criteria to a set of 40 OCTA scans from people with MS, Sjogren syndrome, and uveitis and healthy individuals. The interrater kappa was substantial (κ 0.67). Projection artifacts were the main reason for interrater disagreement. Because artifacts can affect only parts of OCTA images, we agreed that prior definition of a specific region of interest (ROI) is crucial for subsequent OCTA quality assessment. To enhance artifact recognition and interrater agreement on reduced image quality, we designed a scoring guide and OCTA training set. Using these educational tools, 23 raters from 14 different centers reached an almost perfect agreement (κ 0.92) for the rejection of poor-quality OCTA images using the OSCAR-MP criteria. Discussion We propose a 3-step approach for standardized quality control: (1) To define a specific ROI, (2) to assess the occurrence of OCTA artifacts according to the OSCAR-MP criteria, and (3) to evaluate OCTA quality based on the occurrence of different artifacts within the ROI. OSCAR-MP OCTA QC criteria achieved high interrater agreement in an international multicenter study and is a promising QC protocol for application in the context of future clinical trials and studies.
- Open Access
- 29 January 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (4) , 982-990
Retinal ganglion cell loss is associated with future disability worsening in early relapsing–remitting multiple sclerosis
Background and purpose: Thinning of the retinal combined ganglion cell and inner plexiform layer (GCIP) as measured by optical coherence tomography (OCT) is a common finding in patients with multiple sclerosis. This study aimed to investigate whether a single retinal OCT analysis allows prediction of future disease activity after a first demyelinating event.Methods: This observational cohort study included 201 patients with recently diagnosed clinically isolated syndrome or relapsing–remitting multiple sclerosis from two German tertiary referral centers. Individuals underwent neurological examination, magnetic resonance imaging, and OCT at baseline and at yearly follow‐up visits.Results: Patients were included at a median disease duration of 2.0 months. During a median follow‐up of 59 (interquartile range = 43–71) months, 82% of patients had ongoing disease activity as demonstrated by failing the no evidence of disease activity 3 (NEDA‐3) criteria, and 19% presented with confirmed disability worsening. A GCIP threshold of ≤77 μm at baseline identified patients with a high risk for NEDA‐3 failure (hazard ratio [HR] = 1.7, 95% confidence interval [CI] = 1.1–2.8, p = 0.04), and GCIP measures of ≤69 μm predicted disability worsening (HR = 2.2, 95% CI = 1.2–4.3, p = 0.01). Higher rates of annualized GCIP loss increased the risk for disability worsening (HR = 2.5 per 1 μm/year increase of GCIP loss, p = 0.03).Conclusions: Ganglion cell thickness as measured by OCT after the initial manifestation of multiple sclerosis may allow early risk stratification as to future disease activity and progression.
- 29 January 2023
- Published by Wiley in European Journal of Neurology
- Vol. 30 (4) , 982-990
Open AccessRetinal ganglion cell loss is associated with future disability worsening in early relapsing–remitting multiple sclerosis
Background and purpose: Thinning of the retinal combined ganglion cell and inner plexiform layer (GCIP) as measured by optical coherence tomography (OCT) is a common finding in patients with multiple sclerosis. This study aimed to investigate whether a single retinal OCT analysis allows prediction of future disease activity after a first demyelinating event.Methods: This observational cohort study included 201 patients with recently diagnosed clinically isolated syndrome or relapsing–remitting multiple sclerosis from two German tertiary referral centers. Individuals underwent neurological examination, magnetic resonance imaging, and OCT at baseline and at yearly follow‐up visits.Results: Patients were included at a median disease duration of 2.0 months. During a median follow‐up of 59 (interquartile range = 43–71) months, 82% of patients had ongoing disease activity as demonstrated by failing the no evidence of disease activity 3 (NEDA‐3) criteria, and 19% presented with confirmed disability worsening. A GCIP threshold of ≤77 μm at baseline identified patients with a high risk for NEDA‐3 failure (hazard ratio [HR] = 1.7, 95% confidence interval [CI] = 1.1–2.8, p = 0.04), and GCIP measures of ≤69 μm predicted disability worsening (HR = 2.2, 95% CI = 1.2–4.3, p = 0.01). Higher rates of annualized GCIP loss increased the risk for disability worsening (HR = 2.5 per 1 μm/year increase of GCIP loss, p = 0.03).Conclusions: Ganglion cell thickness as measured by OCT after the initial manifestation of multiple sclerosis may allow early risk stratification as to future disease activity and progression.